NRG-GY012 (Endometrial Cancer)

What is the Purpose of this Study?

If you choose to join this study, you will be randomly assigned to 1 of 4 study groups:
- One group will get cediranib alone
- One group will get olaparib and AZD5363 (capivasertib)
- One group will get olaparib and durvalumab (MEDI4736)
- One group will get cediranib and durvalumab (MEDI4736)
What is the Condition Being Studied?
Recurrent, Persistent, or Metastatic Endometrial Cancer

Who Can Participate in this Study?

Adults ages 18+ who:

- Are diagnosed with endometrial cancer that is recurrent, metastatic, or persistent (does not respond to standard treatment)

- Have received at least one previous chemotherapy regimen

For more information about who can join this study, please contact the study team at

Age Group
Participating Institutions

What is Involved?

We are doing this study to find out if different investigational drugs, either on their own or in combination with others, are safe and effective treatments for endometrial cancer that has come back, spread to different parts of the body, or is not responding to standard therapies.

Study Details

Full Title
NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
Principal Investigator

Protocol Number

View on